Last reviewed · How we verify
GFH018
GFH018 is a small molecule that targets the SGLT2 receptor.
GFH018 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GFH018 |
|---|---|
| Sponsor | Zhejiang Genfleet Therapeutics Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
GFH018 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin. By reducing glucose reabsorption, GFH018 helps to improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC (PHASE2)
- A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of GFH018 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GFH018 CI brief — competitive landscape report
- GFH018 updates RSS · CI watch RSS
- Zhejiang Genfleet Therapeutics Co., Ltd. portfolio CI